There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Legend Biotech (LEGN – Research Report), Oculis Holding (OCS – Research Report) and Guardant Health (GH – Research Report) with bullish sentiments.
Legend Biotech (LEGN)
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech, with a price target of $86.00. The company’s shares closed last Monday at $42.97, close to its 52-week low of $42.08.
According to TipRanks.com, Kapoor has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $85.92, which is an 85.7% upside from current levels. In a report issued on May 7, J.P. Morgan also maintained a Buy rating on the stock with a $79.00 price target.
See the top stocks recommended by analysts >>
Oculis Holding (OCS)
Leerink Partners analyst Marc Goodman maintained a Buy rating on Oculis Holding on May 9 and set a price target of $22.00. The company’s shares closed last Monday at $12.07.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
Currently, the analyst consensus on Oculis Holding is a Strong Buy with an average price target of $27.00, implying a 123.1% upside from current levels. In a report issued on April 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $28.00 price target.
Guardant Health (GH)
In a report issued on May 9, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $40.00. The company’s shares closed last Monday at $24.00.
According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $35.45 average price target, representing a 56.2% upside. In a report issued on April 29, Canaccord Genuity also maintained a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN:
- Legend Biotech’s Strong Q1 Growth and Strategic Expansion
- LEGN Upcoming Earnings Report: What to Expect?
- Legend Biotech participates in a conference call with JPMorgan
- European Approval for Legend Biotech’s Myeloma Treatment
- Legend Biotech says Carvykti approved by EC for second-line multiple myeloma
